Publications by authors named "David Grayzel"

Claim this Profile
S
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers.
David Monteith, Emily C Collins, Corinne Vandermeulen, Anne Van Hecken, Eyas Raddad, David Grayzel

Front Pharmacol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Patient-Centered Outcomes in Clinical Trials of Procedural Sedation, Part 1 Efficacy: Sedation Consortium on Endpoints and Procedures for Treatment, Education, and Research Recommendations.
Mark R Williams, Denham S Ward, Douglas Carlson, Joseph Cravero, Franklin Dexter, David Grayzel

Anesth Analg· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US immigration order strikes against biotech.
Jeremy M Levin, Steven H Holtzman, John Maraganore, Paul J Hastings, Ron Cohen, David Grayzel

Nat Biotechnol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model.
Steve Vermeersch, Robert J Benschop, Anne Van Hecken, David Monteith, Victor J Wroblewski, David Grayzel

J Pharmacol Exp Ther· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Site of effect of LY2951742 for migraine prophylaxis--authors' reply.
David W Dodick, Peter J Goadsby, Egilius L H Spierings, Joel C Scherer, Steven P Sweeney, David S Grayzel

Lancet Neurol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs.
Jason A Campagna, Kevin Pojasek, David Grayzel, John Randle, Douglas E Raines

Anesthesiology· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
David W Dodick, Peter J Goadsby, Egilius L H Spierings, Joel C Scherer, Steven P Sweeney, David S Grayzel

Lancet Neurol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
Andrew J Wagner, Rashmi Chugh, Lee S Rosen, Jeffrey A Morgan, Suzanne George, David Grayzel

Clin Cancer Res· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.
David Siegel, Sundar Jagannath, David H Vesole, Ivan Borello, Amitabha Mazumder, David Grayzel

Leuk Lymphoma· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.
Lecia V Sequist, Scott Gettinger, Neil N Senzer, Renato G Martins, Pasi A Jänne, David Grayzel

J Clin Oncol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.
Cong Peng, Julia Brain, Yiguo Hu, Ami Goodrich, Linghong Kong, David Grayzel

Blood· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Jens R Sydor, Emmanuel Normant, Christine S Pien, James R Porter, Jie Ge, David S Grayzel

Proc Natl Acad Sci U S A· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis